| Note |
When night progresses and sleep evades…from the benzodiazepine originators, a new hypnotic…Mogadon. Effective in treating the most common form of insomnia. "Sleep onset difficulty (sleep latency) is one of the most common sleep disorders and approximately 80% of sleep disorders are of this kind." 'Mogadon' has been shown to significantly reduce sleep latency. Low incidence of hangover. After extensive use in thousands of patients, 'Mogadon' has demonstrated a low incidence of hangover. Documented safety record. In a toxicity report involving over 2,000 patients "unwanted effects were attributed to nitrazepam ('Mogadon') in only 3.4% of recipients." Low potential for abuse or dependence. The world-wide literature has revealed few reports of physical and/or psychological dependence with 'Mogadon.' In the therapeutic use, the risk of dependence with benzodiazepines is very low and has been estimated as being probably less than one case per 50 million patient months. Low incidence of interactions. For elderly insomniacs on multiple drug treatments, a particular concern is the potential interaction among concomitant medications. 'Mogadon' does not increase the activity of hepatic microsomal enzymes. Thus, the metabolism and desired clinical effects of other medications are maintained. Flexible dosage range. 'Mogadon' is available as 10 mg and 5 mg scored tablets. Thus 'Mogadon' offers a 2.5 mg to 10 mg h.s. dose flexibility to maximize efficacy and minimize potential adverse effects. Mogadon effective with low incidence of adverse effects in sleep onset insomnia. |
